Results 51 to 60 of about 2,203 (71)

Garis Panduan Audit Akreditasi : Bidang Kejuruteraan dan Senibina [PDF]

, 2018
Aziz, Tuah
core  

Some of the next articles are maybe not open access.

Related searches:

A Review of the Totality of Evidence in the Development of ABP 798, A Rituximab Biosimilar

Immunotherapy, 2022
Dietger Niederwieser, Stanley B Cohen, Gerd R Burmester   +2 more
exaly  

Non-clinical similarity of biosimilar ABP 798 with rituximab reference product

Biologicals, 2021
Helen J Mcbride, Shea Jassem, Scott Kuhns   +2 more
exaly  

Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product

Biologicals, 2020
Scott Kuhns, Mats Wikström, Jennifer L Liu   +2 more
exaly  

A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis

Clinical Pharmacology in Drug Development, 2020
Gerd R Burmester, David Chien, Stanley B Cohen   +2 more
exaly  

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Clinical Rheumatology, 2020
Gerd R Burmester, David Chien, Stanley B Cohen   +2 more
exaly  

Rate and concentration‐dependent effects of UK‐68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and Vmax

British Journal of Pharmacology, 1991
David A Lathrop, Péter P Nánási, Andras Varro   +2 more
exaly  

Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

Targeted Oncology, 2020
Dietger Niederwieser, Cecily J Forsyth, Vincent Delwail   +2 more
exaly  

Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle

Cardiovascular Drugs and Therapy, 1992
David A Lathrop
exaly  

Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay

Journal of Pharmaceutical and Biomedical Analysis, 1991
exaly